Advertisement

Analgetika

  • Rainer H. Böger
  • Gerhard Schmidt

Zusammenfassung

Für die Schmerzbehandlung werden in erster Linie Opioide und nichtopioide Analgetika eingesetzt. Nichtopioide Analgetika wirken zusätzlich antipyretisch, einige auch entzündungshemmend. In manchen Fällen bereitet es Schwierigkeiten, eine eindeutige Trennung von Analgetika gegenüber den Antirheumatika und Antiphlogistika vorzunehmen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Andrade S, Bartels DB, Lange R,Sandford L, Gurwitz J (2016): Safety of metamizole: a systematic review of the literature. J Clin Pharm Ther 41: 459–477Google Scholar
  2. Arzneimittelkommission der deutschen Ärzteschaft (1986): Bundesgesundheitsamt schränkt Anwendungsgebiet von Metamizol-haltigen Monopräparaten ein. Dtsch Ärztebl 83: 3267Google Scholar
  3. Arzneimittelkommission der deutschen Ärzteschaft (2007a): Empfehlungen zur Therapie von Tumorschmerzen. AVP-Sonderheft Therapieempfehlungen, 3. Auflage. Internet: www.akdae.de/35/10/66-Tumorschmerzen-2007-3Auflage.pdf
  4. Arzneimittelkommission der deutschen Ärzteschaft (2007b): Leberschäden unter Flupirtin. Dtsch Ärztebl 104: A3200Google Scholar
  5. Arzneimittelkommission der deutschen Ärzteschaft (2012): Die unkritische Anwendung von Fentanylpflastern erhöht das Risiko für schwerwiegende Nebenwirkungen. Dtsch Ärztebl 109: A724–A725Google Scholar
  6. Bornemann-Cimenti H, Wejbora M, Szilagyi I, Sandner-Kiesling A (2013): Fentanyl zur Behandlung von tumorbedingten Durchbruchschmerzen. Dtsch Ärztebl 110: 271–277Google Scholar
  7. Budd K (1990): Experience with partial antagonists in the treatment of cancer pain. In: Doyle D (Ed). Opioids in the treatment of cancer pain. Royal Society of Medicine, International Congress and Symposium Series No. 146, pp. 51–54Google Scholar
  8. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC (2014): Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine 39: 556–563Google Scholar
  9. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2005): Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94: 825–834Google Scholar
  10. Devulder J (2010): Flupirtine in pain management: pharmacological properties and clinical use. CNS Drugs 24: 867–881Google Scholar
  11. Drover DR, Angst MS, Valle M, Ramaswamy B, Naidu S, Stanski DR, Verotta D (2002): Input characteristics and bioavailability after administration of immediate and a new extended-release formulation of hydromorphone in healthy volunteers. Anesthesiology 97: 827–836Google Scholar
  12. European Medicines Agency (2013): Restrictions in the use of flupirtine-containing medicines – CMDh endorses PRAC recommendation. Internet: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001831.jsp&mid=WC0b01ac058001d126
  13. Frampton JE (2010): Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. Drugs 70: 1719–1743Google Scholar
  14. Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006): Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174: 1589–1594Google Scholar
  15. Garbe E, Jobski K, Schmid U (2012): Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf 21:191–198Google Scholar
  16. Hanks GW, De Conno F, Cherny N et al (Expert Working Group of the Research Network of the European Association for Palliative Care) (2001): Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84: 587–593Google Scholar
  17. Jacox A, Carr DB, Payne R et al (Agency for Health Care Policy and Research (AHCPR) Pharmacological Management) (1994): Recommendations. In: Management of cancer pain. Clinical Practice Guideline No 9. U.S. Department of Health and Human Services, Public Health Service, AHCPR Publication No 94-0592, March, RockvilleGoogle Scholar
  18. Kassenärztliche Bundesvereinigung (2012a): Oxycodon/Naloxon. Wirkstoff aktuell Ausgabe 6/2012. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Oxycodon-Naloxon.pdf
  19. Kassenärztliche Bundesvereinigung (2012b): Tapentadol. Wirkstoff aktuell Ausgabe 3/2012. Internet: www.akdae.de/Arzneimitteltherapie/WA/Archiv/Tapentadol.pdf
  20. Langford RM, Knaggs R, Farguhar-Smith P, Dickenson AH (2016): Is tapentalol different from classical opioids? A review of the evidence. Brit J Pain 10: 217–221Google Scholar
  21. Lauche R, Klose P, Radbruch R, Welsch P, Häuser W (2015): Opioids in chronic noncancer pain – are opioids superior to nonopioid analgesics? A systematic review and metaanalysis to efficacy, tolerability and safety in randomized head-to-head comparisons of opioids versus nonopioid analgesics of at least four weeks duration. Schmerz 29: 85–95Google Scholar
  22. Meissner W, Leyendecker P, Mueller-Lissner S, Nadstawek J, Hopp M, Ruckes C, Wirz S, Fleischer W, Reimer K (2009): A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13: 56–64Google Scholar
  23. Quigley C (2002): Hydromorphone for acute and chronic pain. Cochrane Database Syst Rev. 2002 (1): CD003447Google Scholar
  24. Radbruch L, Elsner F (2005): Palliative Schmerztherapie, Cannabinoide. Internist 46: 1105–1114Google Scholar
  25. Ripamonti C, Fagnoni E, Campa T, Brunelli C, De Conno F (2006): Is the use of transdermal fentanyl inappropriate according to the WHO guidelines and the EAPC recommendations? A study of cancer patients in Italy. Support Care Cancer 14: 400–407Google Scholar
  26. Schubert I, Ihle P, Sabatowski R (2013): Zunahme der Opioidverordnungen in Deutschland zwischen 2000 und 2011. Dtsch Ärztebl 110: 45–51Google Scholar
  27. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC (2008): Trends in use of opioids for non-cancer pain conditions 2000–2005 in commercial and Medicaid insurance plans: the TROUP study. Pain 138: 440–449Google Scholar
  28. The Pain Society (2004): Recommendations for the appropriate use of opioids for persistent non-cancer pain. A consensus statement prepared on behalf of the Pain Society, the Royal College of Anaesthetists, the Royal College of General Practitioners and the Royal College of Psychiatrists. March 2004. Internet: www.britishpain-society.org/pdf/opioids_doc_2004.pdf
  29. Wiffen PJ, Derry S, Naessens K, Bell RF (2015): Oral tapentalol for cancer pain. Cochrane Database Syst Rev. 2015: CD011460Google Scholar
  30. Wilcock A (2009): Prolonged-release naloxone can cause systemic opioid withdrawal. Eur J Pain 13: 1001 (2009)Google Scholar
  31. World Health Organization (WHO) (1986): Cancer Pain Relief. World Health Organization Publications, Geneva, SwitzerlandGoogle Scholar
  32. World Health Organization (WHO) (1996): Cancer pain relief, 2nd edn. World Health Organization Publications, Geneva, SwitzerlandGoogle Scholar
  33. Zhang WY, Po AL (1996): Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain – a metaanalysis. J Clin Pharm Ther 21: 261–282Google Scholar
  34. Zhang WY, Po AL (1997): Do codeine and caffeine enhance the analgesic effect of aspirin? A systematic overview. J Clin Pharm Ther 22: 79–97Google Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Institut für Experimentelle und Klinische PharmakologieUniversitäts-Krankenhaus EppendorfHamburgDeutschland
  2. 2.Institut für Pharmakologie und Toxikologie der UniversitätGöttingenDeutschland

Personalised recommendations